Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.

Rubenstein JL, Treseler PA, Stewart PJ.

J Clin Oncol. 2011 Jul 10;29(20):e595-7. doi: 10.1200/JCO.2011.34.7252. Epub 2011 Apr 25. No abstract available.

2.

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS.

Cancer. 2011 Nov 15;117(22):5058-66. doi: 10.1002/cncr.26135. Epub 2011 Apr 14.

3.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS.

Ann Oncol. 2011 Jul;22(7):1622-7. doi: 10.1093/annonc/mdq626. Epub 2011 Jan 12.

PMID:
21228334
4.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM.

J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7.

PMID:
18606983
5.

Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.

Ohguro N, Hashida N, Tano Y.

Arch Ophthalmol. 2008 Jul;126(7):1002-3. doi: 10.1001/archopht.126.7.1002. No abstract available.

PMID:
18625954
6.

Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type.

Savini P, Lanzi A, Foschi FG, Marano G, Stefanini GF.

Ann Hematol. 2014 Feb;93(2):333-4. doi: 10.1007/s00277-013-1787-0. Epub 2013 May 17. No abstract available.

PMID:
23680870
7.

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS.

Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23. Review.

PMID:
25712458
8.

Ocular involvement as first sign of isolated CNS relapse in diffuse large B-cell lymphoma.

Ferrari A, Luppi M, Lazzerini A, Potenza L, Cavallini GM, Torelli G.

Lancet Oncol. 2006 Mar;7(3):274. No abstract available.

PMID:
16510339
9.

Lenalidomide-associated hypothyroidism.

Menon S, Habermann T, Witzig T.

Leuk Lymphoma. 2007 Dec;48(12):2465-7. No abstract available.

PMID:
18067027
10.

Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Ivanov V, Coso D, Chetaille B, Esterni B, Olive D, Aurran-Schleinitz T, Schiano JM, Stoppa AM, Broussais-Guillaumot F, Blaise D, Bouabdallah R.

Leuk Lymphoma. 2014 Nov;55(11):2508-13. doi: 10.3109/10428194.2014.889822. Epub 2014 Mar 17.

PMID:
24506467
11.

Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type.

Swaika A, Menke DM, Jain MK, Sher T.

Ann Hematol. 2015 May;94(5):895-6. doi: 10.1007/s00277-014-2253-3. Epub 2014 Nov 15. No abstract available.

PMID:
25394720
12.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.

PMID:
25135992
13.

Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.

Dalle JH, Leblond P, Decouvelaere A, Yakoub-Agha I, Preudhomme C, Nelken B, Mazingue F.

Leukemia. 2003 Oct;17(10):2056-7. No abstract available.

PMID:
14513060
14.

Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.

Ivanov V, Tabouret E, Chuto G, Chetaille B, Fezoui H, Coso D, Rey J, Aurran-Schleinitz T, Schiano JM, Stoppa AM, Blaise D, Bouabdallah R.

Leuk Lymphoma. 2010 Sep;51(9):1758-60. doi: 10.3109/10428194.2010.497886. No abstract available.

PMID:
20629527
15.

New developments in the management of diffuse large B-cell lymphoma.

Habermann TM.

Hematology. 2012 Apr;17 Suppl 1:S93-7. doi: 10.1179/102453312X13336169156014. Review.

PMID:
22507791
16.

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.

Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6. doi: 10.1016/j.clml.2011.02.001. Epub 2011 May 4.

PMID:
21859554
17.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczkowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo ML, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network.

Lancet Oncol. 2016 Mar;17(3):319-31. doi: 10.1016/S1470-2045(15)00559-8. Epub 2016 Feb 16.

PMID:
26899778
18.

Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.

Zinzani PL, Pellegrini C, Derenzini E, Argnani L, Pileri S.

Hematol Oncol. 2013 Dec;31(4):223-4. doi: 10.1002/hon.2049. Epub 2013 Apr 26. No abstract available.

PMID:
23620452
19.

The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).

Dawar R, Hernandez-Ilizaliturri F.

Best Pract Res Clin Haematol. 2012 Jun;25(2):185-90. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Review.

PMID:
22687454
20.

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.

Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, Argnani L, Berti E, Derenzini E, Pileri S, Baccarani M.

Leuk Lymphoma. 2011 Aug;52(8):1585-8. doi: 10.3109/10428194.2011.573031. Epub 2011 Apr 19. No abstract available.

PMID:
21504290

Supplemental Content

Support Center